Interestingly, increased expression of TP53 has been implicated in AD, whereas p53 inhibition attenuates liver injury in NAFLD mouse models, which suggests an inverse relationship [111]. The gene discussed is TP53; the disease is metabolic dysfunction-associated steatotic liver disease.